Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 24, 2024 - Issue 3
Submit an article Journal homepage
212
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece

George Gourzoulidisa Health Through Evidence, Athens, GreeceCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-7239-9829View further author information
ORCID Icon,
Oresteia Zisimopouloub Pfizer Hellas, Athens, GreeceView further author information
,
Andrianos Liavasb Pfizer Hellas, Athens, GreeceView further author information
&
Charalampos Tzanetakosa Health Through Evidence, Athens, GreeceView further author information
Pages 375-385 | Received 03 Aug 2023, Accepted 07 Nov 2023, Published online: 25 Nov 2023

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.